MEDI 3506

Drug Profile

MEDI 3506

Alternative Names: MEDI3506

Latest Information Update: 22 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MedImmune
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 1 receptor-like 1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic obstructive pulmonary disease

Most Recent Events

  • 15 May 2017 Phase-I clinical trials in Chronic obstructive pulmonary disease in USA (SC and IV) (NCT03096795)
  • 05 Apr 2017 MedImmune plans a phase I trial for Chronic obstructive pulmonary disease in United Kingdom (NCT03096795)
  • 05 Apr 2017 Preclinical trials in Chronic obstructive pulmonary disease in USA before April 2017 (SC and IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top